Investigation of Safety and Tolerability of ASP3652 Based on Clinical Studies of Cerebrospinal Fluid Transfer After Multiple Doses and Exposure After Single Doses at High Dose Levels
posted on 2020-07-24, 10:22authored byMasaomi Takizawa, Dirk Cerneus, Ingrid Michon, Sanne Rijnders, John Meijer, Akiyoshi Someya, Yuichiro Sato
The above summary slide represents
the opinions of the authors. For a full list of declarations, including funding
and author disclosure statements, please see the full text online (see “read
the peer-reviewed publication” opposite).